Sociedad Americana de Hirudoterapia

Effect of O-glycosylation and tyrosine sulfation of leech-derived peptides on binding and inhibitory activity against thrombin

Research article published in Chemical communications (2011)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosHsieh YS et al. · Chemical communications, 2011

Abstract

Synthesis of sulfated and unsulfated (glyco)peptide fragments of Hirudin P6 (a potent anticoagulant from the leech Hirudinaria manillensis) is described. The effect of O-glycosylation and tyrosine sulfation on thrombin binding and peptidolytic activity was investigated, together with the inhibition of fibrinogen cleavage.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsBinding SitesGlycosylationMolecular ConformationPeptidesStructure-Activity RelationshipThrombinTyrosine

Resumen

Effect of O-glycosylation and tyrosine sulfation of leech-derived peptides on binding and inhibitory activity against thrombin.

Por qué esto importa para la hirudoterapia

This study describes the synthesis of sulfated and unsulfated (glyco)peptide fragments of Hirudin P6—a potent anticoagulant identified from the leech Hirudinaria manillensis—and investigates how O-glycosylation and tyrosine sulfation affect thrombin binding, peptidolytic activity, and inhibition of fibrinogen cleavage. Because Hirudin P6 is a leech-derived peptide, characterizing these structural modifications helps clarify how specific chemical features influence its interaction with thrombin. The work is limited to isolated, chemically synthesized peptide fragments studied in vitro; it does not evaluate whole leeches, live hirudotherapy, or any clinical outcome.

Citación

Effect of O-glycosylation and tyrosine sulfation of leech-derived peptides on binding and inhibitory activity against thrombin

Hsieh YS et al. · Chemical communications, 2011

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.